Search Results

Retrospective Observational Study of Hormone Receptor Positive (HR+) and HER2-low (IHC1+ or 2+ with ISH negative) and HER2- ultralow (IHC0 with membrane staining) Metastatic Breast Cancer (MBC) Brief Summary: This is a multicenter retrospective observational study in participants with HR+ HER2-low and HER2-ultralow MBC. ENHERTU treatment should have been received on or after September 2022…

An Interventional Phase 3, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer MOA: F-08634404 is a PD-1xVEGF bispecific antibody. Key Eligibility Criteria: LA (Stage IIIB/C) or met (Stage IV) squamous or…

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer – CA266-0003 MOA: Pumitamig (BMS-986545/BNT327) is a bispecific antibody targeting PD-L1 and VEG-F. Key Eligibility Criteria: Previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma,…

A randomized, Phase 3, open-label study to evaluate PF-08046054/SGN-PDL1V vs Docetaxel in adult participants with previously-treated programmed cell death ligand (PD-L1) positive non-small cell lung cancer (NSCLC) MOA: F-08046054/SGN-PDL1V is an anti-PD-L1 ADC with a MMAE payload Key Eligibility Criteria: Histologically or cytologically documented unresectable Stage IIIB, IIIC, IV NSCLC not eligible for definitive chemoradiotherapy.…

Dr. Ahmad Cheema is a fellowship-trained, board-certified medical oncologist and hematologist. He earned his medical degree from the Services Institute of Medical Sciences in Pakistan, followed by Internal Medicine residency training at the Icahn School of Medicine at Mount Sinai/St. Luke’s-Roosevelt Hospital Center. He then completed his Hematology and Oncology fellowship at West Virginia University.…

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations Brief Summary: The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid…